Open Access Journals

All Science and Engineering articles published in our Open Access journals are freely accessible to read, download and share..

Publish Your Research Papers

Annex Publishers is a center for researchers and scientists who work hard to bring a far higher tomorrow for humanity.
  • Annex Publishers

    Annex publishers is an Open Access publication model which allows the publication of articles to the world through this community. We provide you the asset of interaction with the most researchers from the scientific community. Anyone can freely access the articles printed under Annex publishers.
  • Why Open Access?

    Open access provides an unlimited access to journals and publications, with a perfect platform for thousands of researchers to form jointly for the development of science. Open Access assists in accelerating the scientific discovery, encourage innovation, enhance education and refresh the economy to build up the knowledge of the general public.
Submit Manuscript

Recent Articles

Effect of Hot Water Treatment on DNA Quality of Sweet Orange (Citrus sinensis (L) osbeck) Fruits

In this study, mature sweet orange fruits (amber variety) were separately subjected to hot water treatments: 35 o C for 25 and 30 minutes; 45 o C for 15, 20 and 25 minutes; 48 o C for 10, 15 and 20 minutes; 50 o C for 10, 15 and 20 minutes; 53 o C for 10 minutes and 55 o C for 5 minutes and were thereafter assessed for their DNA quality while unheated fruits served as control. The DNA quality was done by rapid random polymorphic DNA-polymersae chain reaction (RAPD-PCR) on the extracted DNA from each set of treated fruits using the RAPD primer OPR 02 (5’ – CAC AGC TGC C-3’).

Comparative Study for Efficacy and Safety of Biosimilar Infliximab in Patients with Active Rheumatoid Arthritis on a stable Dose of Methotrexate

The present study evaluated the efficacy and safety of biosimilar infliximab in patients with active rheumatoid arthritis on a stable dose of methotrexate. Subjects were assigned randomly to either study infliximab or reference infliximab product in an approved dose of 3 mg/kg as an intravenous infusion at week 0, followed by similar doses at Weeks 2, 6 and 14. Primary efficacy endpoint was the proportion of subjects achieving ACR20 criteria at week 16 and secondary efficacy assessment included proportion of subjects achieving ACR20, ACR50 and ACR70 at week 16. In the open-label phase, all responders were followed till week 54. The non-responders entered a follow-up phase for immunogenicity and safety for an additional 3 months.